Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

11 results
Display

Molecular Epidemiology of Hepatitis B Virus

Kao JH

Although safe and effective vaccines for hepatitis B virus (HBV) have been available for nearly three decades, this virus kills at least 600,000 people annually worldwide and remains the leading...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease

Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ

Background/Aims: Fatty liver disease is defined as a cluster of diseases with heterogeneous etiologies, and its definition continues to evolve. The novel conceptional criteria for metabolic dysfunction-associated fatty liver disease...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma

Wu JW, Kao JH, Tseng TC

Patients with chronic hepatitis B virus (HBV) infection are at risk of developing hepatocellular carcinoma (HCC), and serum markers reflecting viral replication are potential predictors for HCC development. Besides the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis

Liu CH, Chen CY, Su WW, Liu CJ, Lo CC, Huang KJ, Chen JJ, Tseng KC, Chang CY, Peng CY, Shih YL, Huang CS, Kao WY, Yang SS, Tsai MC, Wu JH, Chen PY, Su PY, Hwang JJ, Fang YJ, Lee PL, Tseng CW, Lee FJ, Lai HC, Hsieh TY, Chang CC, Chang CH, Huang YJ, Kao JH

Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods: We included 107 patients with Child-Pugh...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Direct comparison of biopsy techniques for hepatic malignancies

Huang SC, Liang JD, Hsu SJ, Hong TC, Yang HC, Kao JH

Background/Aims: The core needle biopsy (CNB), fine needle aspiration cytology (FNAC) and touch imprint cytology (TIC) are commonly used tools for the diagnosis of hepatic malignancies. However, little is known...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Hsu YC, Tseng CH, Kao JH

Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk stratification of HBV infection in Asia-Pacific region

Kao JH

Hepatitis B virus (HBV) infection is the major etiology of chronic liver disease worldwide and thus a global health problem, especially in Asia-Pacific region. The long-term outcomes of Asian HBV...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas

Lan TY, Lin YC, Tseng TC, Yang HC, Kao JH, Cheng CF, Lee TJ, Huang SC, Lu CH, Li KJ, Hsieh SC

Background/Aims: Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New perspectives of biomarkers for the management of chronic hepatitis B

Lin CL, Kao JH

With recent advances in molecular and genomic investigations, the impact of hepatitis B viral and host factors on the progression of chronic HBV infection has been explored. For viral factors,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program

Lu MY, Huang CF, Hung CH, Tai C, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang S, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin C, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, Yu ML, TACR Study Group

Background/Aims: Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases

Cheng PN, Chen WJ, Hou CJY, Lin CL, Chang ML, Wang CC, Chang WT, Wang CY, Lin CY, Hung CL, Peng CY, Yu ML, Chao TH, Huang JF, Huang YH, Chen CY, Chiang CE, Lin HC, Li YH, Lin TH, Kao JH, Wang TD, Liu PY, Wu YW, Liu CJ

Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr